Cocrystal Pharma Inc (COCP)

$ 1.17
-0.02 (-1.68%)
Buy
Symbol COCP
Price $ 1.17
Beta 0.744
Volume Avg. 14.77M
Market Cap 0.08B
Shares () -
52 Week Range 0.76-3.46
1y Target Est -
DCF Unlevered -
DCF Levered -
ROE -21.42% Sell
ROA -17.79% Sell
Operating Margin -
Debt / Equity 3.31% Neutral
P/E -
P/B 1.28 Strong Buy
Annual
Quarter

Earnings

Consensus EPS

Upgrades & Downgrades

Cocrystal Pharma Announces Closing of $40 Million Bought Deal

Cocrystal Pharma Announces Closing of $40 Million Bought Deal

BOTHELL, Wash., May 07, 2021 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc.  (Nasdaq: COCP), (“Cocrystal” or the “Company”), a clinical-stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication machin... ...

GlobeNewsWire
Rookie Traders Get Crushed By Cocrystal Pharma Stock

Rookie Traders Get Crushed By Cocrystal Pharma Stock

The trading in biotechnology company Cocrystal Pharma, Inc. (NASDAQ: COCP) is a good example of how inexperienced traders can lose a lot of money. What Happened: Cocrystal closed Tuesday at $2.14, a gain of over 70%. ...

Benzinga
Cocrystal stock pulls back sharply after stock offering priced to the public at a deep discount

Cocrystal stock pulls back sharply after stock offering priced to the public at a deep discount

Shares of Cocrystal Pharma Inc. plunged 28.3% in active premarket trading, after the biotechnology company announced a $40 million common stock offering. The company announced the offering Tuesday's closing bell, after the stock rocketed 72.6% on Tue... ...

Market Watch
Cocrystal Pharma Shares Plunge On $40M Equity Raise At 28% Discount

Cocrystal Pharma Shares Plunge On $40M Equity Raise At 28% Discount

Cocrystal Pharma Inc (NASDAQ: COCP) has entered into an underwriting agreement with H.C. Wainwright & Co LLC, under which the underwriter has agreed to purchase 26 million shares at $1.54 per share. ...

Benzinga
Cocrystal Pharma Announces $40 Million Bought Deal Offering of Common Stock

Cocrystal Pharma Announces $40 Million Bought Deal Offering of Common Stock

BOTHELL, Wash., May 04, 2021 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc.  (Nasdaq: COCP), (“Cocrystal” or the “Company”), a clinical-stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication machin... ...

GlobeNewsWire
Cocrystal stock doubles on massive volume a day after progress announced on coronavirus drug candidates

Cocrystal stock doubles on massive volume a day after progress announced on coronavirus drug candida...

Shares of Cocrystal Pharma Inc. more than doubled on massive record volume in afternoon trading Tuesday, a day after the biotechnology company said it has made "progress" in developing antiviral drug candidates that target coronaviruses, including th... ...

Market Watch
Why Cocrystal Pharma, Chemocentryx, Neuronetics And BioLineRx Are Moving Today

Why Cocrystal Pharma, Chemocentryx, Neuronetics And BioLineRx Are Moving Today

Cocrystal Pharma, Inc. (NASDAQ: COCP), ChemoCentryx, Inc. (NASDAQ: CCXI), Neuronetics, Inc. (NASDAQ: STIM) and BioLineRx Ltd. (NASDAQ: BLRX) are among the biggest health care movers Tuesday. ...

Benzinga
COCP Stock: From $1.24 to $1.98 (59.68% Increase) Pre-Market Explanation

COCP Stock: From $1.24 to $1.98 (59.68% Increase) Pre-Market Explanation

The stock price of Cocrystal Pharma, Inc. (Nasdaq: COCP) increased 59.68% pre-market as it went from $1.24 to $1.98. This is why it happened. ...

Pulse2
Cocrystal Pharma Stock Gains After Laying Out Plans To Launch Another COVID-19 Antiviral Candidate

Cocrystal Pharma Stock Gains After Laying Out Plans To Launch Another COVID-19 Antiviral Candidate

Cocrystal Pharma Inc (NASDAQ: COCP) has announced progress on its COVID-19 antiviral drug candidates that target coronaviruses, including SARS-CoV-2, and it also plans to launch a second COVID-19 program with additional antiviral compounds for develo... ...

Benzinga
Cocrystal Pharma to Participate in the Virtual 33rd Annual Roth Conference

Cocrystal Pharma to Participate in the Virtual 33rd Annual Roth Conference

BOTHELL, Wash., March 09, 2021 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc.  (Nasdaq: COCP), (“Cocrystal” or the “Company”), a clinical-stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication mach... ...

GlobeNewsWire

About


Dr. Gary Wilcox
Healthcare
Biotechnology
Nasdaq Capital Market

Cocrystal Pharma, Inc. is a biotechnology company, which engages in the discovery and development of novel antiviral therapeutics. The company is headquartered in Bothell, Washington and currently employs 10 full-time employees. The firm focuses on discovering and developing novel antiviral therapeutics as treatments for serious and/or chronic viral diseases. The firm focuses on developing and commercializing antiviral drug candidates for the treatment and prophylaxis of hepatitis C, influenza and norovirus. The firm uses computational methods to screen and design product candidates using its cocrystal structural information. The Company’s Hepatitis C Virus (HCV) Non-Nucleoside Polymerase Inhibitor CC-31244 is a pan-genotypic inhibitor of NS5B polymerase for the treatment of hepatitis C infection. The Company’s CC-42344 is a novel PB2 inhibitor for the treatment of influenza infection. The firm is also focused on identifying and developing nucleoside and non-nucleoside polymerase inhibitors for the treatment of Norovirus infections.